342 related articles for article (PubMed ID: 18248653)
1. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.
Parekh M; Fendrick AM; Ladabaum U
Aliment Pharmacol Ther; 2008 Apr; 27(8):697-712. PubMed ID: 18248653
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of colonoscopy or faecal immunochemical test for population-based organised colorectal cancer screening.
Areia M; Fuccio L; Hassan C; Dekker E; Dias-Pereira A; Dinis-Ribeiro M
United European Gastroenterol J; 2019 Feb; 7(1):105-113. PubMed ID: 30788122
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
5. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
9. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study.
Ladabaum U; Mannalithara A; Mitani A; Desai M
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):318-328. PubMed ID: 31796524
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
12. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.
Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Savarino JE; van Ballegooijen M; Kuntz KM; Zauber AG
J Natl Cancer Inst; 2010 Aug; 102(16):1238-52. PubMed ID: 20664028
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of screening for colorectal cancer in the general population.
Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
[TBL] [Abstract][Full Text] [Related]
17. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
18. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG; Habbema JD; Kuipers EJ
J Natl Cancer Inst; 2009 Oct; 101(20):1412-22. PubMed ID: 19779203
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
